How is SS-31 dosed and mixed?

Draw to

unitsmL

0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe

051015202530 01020304050 0102030405060708090100 00.511.522.53 05101520 010203040

    mL
    Most often logged by Milligram users
    Syringe scale
    Syringe

    Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.

    Save to Milligram
    How often

    Open in Milligram shows once the calculator has a result.

    Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.

    Open in Milligram is off while the draw is under one unit. Check the dose and its unit.

    Open in Milligram adds SS-31 (Elamipretide) and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.

    The US label for Forzinity (elamipretide), for Barth syndrome in patients weighing at least 30 kg, gives 40 mg under the skin once daily, or 20 mg under the skin once daily in adults with an eGFR under 30 mL/minute who are not on dialysis.1

    The guide's example

    1 mg of SS-31 (Elamipretide) from a 10 mg vial mixed with 1 mL is 10 units on a U-100 syringe.

    Every vial at a glance. Pick a cell to draw it on the syringe.

    Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
    Vial1 mL of water2 mL of water
    10 mg58% set up910 mg/mL: 1 mg is 10 units, 2 mg is 20 units, 5 mg is 50 units5 mg/mL: 1 mg is 20 units, 2 mg is 40 units, 5 mg is 100 units
    50 mg32% set up950 mg/mL: 1 mg is 2 units, 2 mg is 4 units, 5 mg is 10 units25 mg/mL: 1 mg is 4 units, 2 mg is 8 units, 5 mg is 20 units

    Most often logged by Milligram users: 1 mg, 34% logged.9

    Jump to a vial 10 mg 50 mg

    Mixing the 10 or 50 mg vials people log, in syringe units

    The label's product is an aqueous solution of 280 mg in 3.5 mL (80 mg/mL) in single-patient-use vials, not a powder.1 Searches of PubMed for elamipretide with stability, reconstitution or lyophilisation turned up no stability or reconstitution study of a powder, so none of the sources here gives a water volume for a powder. Among people who logged SS-31, 58% set up a 10 mg vial and 32% a 50 mg vial.9 The mixes people set up were 10 mg with 1 mL (29%), 10 mg with 2 mL (23%), 50 mg with 2 mL (15%) and 50 mg with 3 mL (13%).9 The doses people set up were 1 mg (34%), 2 mg (23%) and 5 mg (14%).9

    1 mg of SS-31 (Elamipretide) from a 10 mg vial mixed with 1 mL is 10 units on a U-100 syringe.

    The calculator is at the top of the page

    Doses and schedules: label and trials

    The label for Forzinity, approved under accelerated approval for adult and pediatric patients with Barth syndrome weighing at least 30 kg, gives 40 mg under the skin once daily at the same time each day.1 For adults with an eGFR under 30 mL/minute who are not on dialysis it gives 20 mg under the skin once daily.1 FDA's review says the sponsor ran no dose-ranging study in people with Barth syndrome.2 A registry record for SPIMD-301 (NCT05162768) describes a 48-week trial of 60 mg a day under the skin or placebo, 1:1, in primary mitochondrial disease from nuclear DNA mutations.3

    TrialDose and schedulePeopleLength
    TAZPOWER (SPIBA-201), Thompson4540 mg a day under the skin, or placebo, crossover12 with Barth syndrome12 weeks each, 4-week washout
    TAZPOWER extension, Thompson540 mg a day under the skin, open labelTen with Barth syndrome entered, 8 reached week 168168-week extension; the label says three of the 8 received it for 192 weeks1
    MMPOWER-3, Karaa640 mg once daily under the skin, or placebo, 1:1218 adults with primary mitochondrial myopathy (109 per arm)24 weeks
    ReCLAIM-2, Ehlers740 mg a day under the skin, or placebo176 with age-related macular degeneration (117 elamipretide, 59 placebo)48 weeks
    PROGRESS-HF, Butler84 mg or 40 mg once daily under the skin, or placebo, 1:1:171 with heart failure with reduced ejection fraction28 days

    Where it is injected

    The label says to inject under the skin in the abdomen (at least 2 inches from the navel) or the outer thigh, and to rotate the site daily.1 It reports comparable exposure after injection into the thigh or the abdomen.1 Of the people who logged SS-31, 98% logged it under the skin.9

    Storage

    The label says to store vials refrigerated at 2 to 8 degrees C, not frozen.1 It says that after the first dose the vial in use can be kept refrigerated at 2 to 8 degrees C or at 20 to 25 degrees C, and to discard vials 8 days after first opening.1 Those conditions are the label's, for its solution of 280 mg in 3.5 mL, not for a vial mixed from powder.1

    Frequently asked questions

    How was the 40 mg dose chosen?

    FDA's review says the sponsor based it mainly on SPIMM-201, a crossover study in 36 people aged 16 to 65 with mitochondrial myopathy that gave placebo or 0.02, 0.20 or 0.50 mg/kg into a vein once daily for 5 days.2 It adds that the later phase 3 trial, SPIMM-301, at 40 mg in people with primary mitochondrial myopathy, showed no improvement in 6-minute walk distance except in a post-hoc subgroup with nuclear DNA mutations, which raised uncertainty about the 40 mg daily dose for Barth syndrome.2

    Is SS-31 the same as elamipretide?

    Yes: Thompson's Barth syndrome trial report writes SS-31 as elamipretide, and the US label says Forzinity contains elamipretide.41

    How the logged figures are counted

    Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.

    References

    1. US Food and Drug Administration (label on DailyMed, Stealth BioTherapeutics). FORZINITY (elamipretide hydrochloride) injection, prescribing information and Instructions for Use (DailyMed, version 11). 2026. dailymed.nlm.nih.gov
    2. US Food and Drug Administration, Center for Drug Evaluation and Research. Integrated review, NDA 215244, Forzinity (elamipretide). 2025. accessdata.fda.gov
    3. ClinicalTrials.gov. Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (NCT05162768). 2025. clinicaltrials.gov
    4. Journal article (PMC, open access). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome (Thompson et al.). 2021. pmc.ncbi.nlm.nih.gov
    5. Genetics in Medicine (PubMed abstract). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER (abstract). 2024. pubmed.ncbi.nlm.nih.gov
    6. Neurology (PMC, open access). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. 2023. pmc.ncbi.nlm.nih.gov
    7. Ophthalmology Science (PMC, open access). ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration. 2025. pmc.ncbi.nlm.nih.gov
    8. Journal of Cardiac Failure (PubMed abstract). Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial (abstract). 2020. pubmed.ncbi.nlm.nih.gov
    9. Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted